SCHEDULE: Eventide Asset Management Boosts Evolent Health Stake

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 5.4% beneficial ownership stake in Evolent Health, Inc., totaling 6,292,511 Class A Common Stock shares as of September 30, 2025.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John collectively reported beneficial ownership of 6,292,511 shares of Evolent Health, Inc.'s Class A Common Stock.
• This represents a 5.4% stake in the company as of September 30, 2025.
• Eventide Asset Management holds sole voting and dispositive power over all 6,292,511 shares.
• Finny Kuruvilla and Robin C. John share voting and dispositive power over the same 6,292,511 shares.
• The shares are held across various Eventide funds and accounts, including Eventide Gilead Fund (3,900,000 shares, 3.3%), Eventide Healthcare & Life Sciences Fund (2,356,913 shares, 2.0%), Eventide Small Cap ETF (88 shares, 0.0%), and Eventide separately managed accounts (35,510 shares, 0.1%).
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing control of Evolent Health, Inc.

Sentiment

Score: 6

Explanation: The filing reports a significant beneficial ownership stake by a reputable investment firm, which can be interpreted as a positive signal of institutional confidence in the issuer. However, as a routine ownership disclosure, it lacks operational or financial performance details to warrant a strong sentiment.

Positives

• Significant institutional investment by Eventide Asset Management, indicating confidence in Evolent Health, Inc.
• The collective 5.4% stake suggests a notable long-term passive investment position by a reputable asset manager.

Risks

• The reporting persons explicitly state that the securities were not acquired for the purpose of changing or influencing control, which mitigates immediate governance risks from this specific filing.
• No other specific risks related to Evolent Health, Inc. are detailed in this ownership report.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Evolent Health, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Evolent Health, Inc.

Industry Context

This filing reflects a routine disclosure of a significant passive investment by an institutional asset manager in a publicly traded healthcare technology company. Such disclosures are common and indicate ongoing portfolio management activities within the investment industry.

Stakeholder Impact

• Shareholders may view the significant institutional ownership as a positive indicator of long-term confidence in the company's value.
• The filing reinforces the perception of Evolent Health, Inc. as an attractive investment for institutional funds.

Key Dates

Recommendation

While the filing indicates institutional confidence through a significant ownership stake, a Schedule 13G primarily serves as a disclosure of beneficial ownership and does not provide sufficient financial performance data, strategic updates, or forward-looking guidance to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await more comprehensive financial reports or operational updates to make a more informed decision.

Keywords

Evolent Health, Eventide Asset Management, beneficial ownership, Schedule 13G, institutional investment, Class A Common Stock, healthcare technology, investment adviser